Press release
Breast Cancer Pipeline Assessment 2024: FDA, EMA, PDMA Approvals, Clinical Trials, Drugs, Mechanism of Action, Route of Administration and Companies by DelveInsight
Breast Cancer Pipeline
"Breast Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Breast Cancer Market.
The Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ https://www.delveinsight.com/report-store/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Breast Cancer Pipeline Report:
• Companies across the globe are diligently working toward developing novel Breast Cancer treatment therapies with a considerable amount of success over the years.
• Breast Cancer companies working in the treatment market are RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., otehrs, are developing therapies for the Breast Cancer treatment
• Emerging Breast Cancer therapies such as Disitamab Vedotin, EndoTAG®-1 (SB05), Stenoparib (2X-121), U3-1402, KN026, trastuzumab duocarmazine, HS-10342, MRG002, ARX788, DHP107, PMD-026, PVX-410, HX008, Tenalisib, MEN1611, SM-88, HMPL-013, ODM-209, HC-5404-FU, RP12146, PU-H71, NOV120101, SC10914, Eftilagimod Alpha, ARV-471, E7090, DZD1516, G1T38, Sitravatinib, TQ-B211, B003, PF-06873600, OTS167PO, AND019, DAN-222, Enobosarm, Futibatinib, LY3484356, Lasofoxifene, MCLA-128, huMNC2-CAR44 CAR T cells, REM-001, GNC-035, RGT-419B, Hemay022, SCR-6852, and others are expected to have a significant impact on the Breast Cancer market in the coming years.
• In November 2023, Pfizer announces that its new breast cancer drug, palbociclib, has been approved by the FDA for the treatment of patients with HER2-positive metastatic breast cancer. Palbociclib is a CDK4/6 inhibitor that works by blocking the growth and spread of cancer cells.Merck announces that its new breast cancer drug, pembrolizumab, has been approved by the FDA for the treatment of patients with triple-negative breast cancer (TNBC). Pembrolizumab is an immunotherapy drug that works by boosting the body's immune system to fight cancer cells. Roche announces that its new breast cancer drug, tucatinib, has been approved by the FDA for the treatment of patients with HER2-positive advanced or metastatic breast cancer. Tucatinib is a TKI that works by blocking the HER2 protein, which is involved in the growth and spread of cancer cells.
Breast Cancer Overview
Breast cancer is a prevalent malignancy arising from abnormal cell growth in breast tissue, affecting primarily women but also men. It typically presents as a lump or mass in the breast, changes in breast size or shape, discharge, or skin changes like dimpling or redness. Risk factors include advancing age, family history, genetic mutations (such as BRCA1 and BRCA2), hormonal factors like early or late menopause, obesity, and alcohol consumption. Diagnosis involves mammography, ultrasound, biopsy, and imaging studies to determine the extent of the disease. Treatment options vary depending on factors like tumor size, stage, and hormone receptor status, and may include surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, or a combination thereof. Early detection through screening mammograms and advances in treatment have significantly improved survival rates, emphasizing the importance of regular breast cancer screening and awareness.
Get a Free Sample PDF Report to know more about Breast Cancer Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Breast Cancer Route of Administration
Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Breast Cancer Molecule Type
Breast Cancer Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Breast Cancer Pipeline Therapeutics Assessment
• Breast Cancer Assessment by Product Type
• Breast Cancer By Stage and Product Type
• Breast Cancer Assessment by Route of Administration
• Breast Cancer By Stage and Route of Administration
• Breast Cancer Assessment by Molecule Type
• Breast Cancer by Stage and Molecule Type
DelveInsight's Breast Cancer Report covers around 130+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Breast Cancer product details are provided in the report. Download the Breast Cancer pipeline report to learn more about the emerging Breast Cancer therapies- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Breast Cancer Pipeline Analysis:
The Breast Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Breast Cancer Treatment.
• Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Breast Cancer market.
Download Sample PDF Report to know more about Breast Cancer drugs and therapies- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of Breast Cancer Pipeline Drug Insight
• Coverage: Global
• Key Breast Cancer Companies: RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., and others.
• Key Breast Cancer Therapies: Disitamab Vedotin, EndoTAG®-1 (SB05), Stenoparib (2X-121), U3-1402, KN026, trastuzumab duocarmazine, HS-10342, MRG002, ARX788, DHP107, PMD-026, PVX-410, HX008, Tenalisib, MEN1611, SM-88, HMPL-013, ODM-209, HC-5404-FU, RP12146, PU-H71, NOV120101, SC10914, Eftilagimod Alpha, ARV-471, E7090, DZD1516, G1T38, Sitravatinib, TQ-B211, B003, PF-06873600, OTS167PO, AND019, DAN-222, Enobosarm, Futibatinib, LY3484356, Lasofoxifene, MCLA-128, huMNC2-CAR44 CAR T cells, REM-001, GNC-035, RGT-419B, Hemay022, SCR-6852, and others.
• Breast Cancer Therapeutic Assessment: Breast Cancer current marketed and Breast Cancer emerging therapies
• Breast Cancer Market Dynamics: Breast Cancer market drivers and Breast Cancer market barriers
Request for Sample PDF Report for Breast Cancer Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Breast Cancer Report Introduction
2. Breast Cancer Executive Summary
3. Breast Cancer Overview
4. Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5. Breast Cancer Pipeline Therapeutics
6. Breast Cancer Late Stage Products (Phase II/III)
7. Breast Cancer Mid Stage Products (Phase II)
8. Breast Cancer Early Stage Products (Phase I)
9. Breast Cancer Preclinical Stage Products
10. Breast Cancer Therapeutics Assessment
11. Breast Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Breast Cancer Companies
14. Breast Cancer Key Products
15. Breast Cancer Unmet Needs
16 . Breast Cancer Market Drivers and Barriers
17. Breast Cancer Future Perspectives and Conclusion
18. Breast Cancer Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Biochips Market: https://www.delveinsight.com/report-store/biochips-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Dysthymia Market: https://www.delveinsight.com/report-store/major-depressive-disorder-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-epidemiology-forecast
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-market
• Ocular Motility Disturbance Market: https://www.delveinsight.com/report-store/ocular-motility-disturbance-market
• Vitamin A Deficiency Market: https://www.delveinsight.com/report-store/vitamin-a-deficiency-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Breast Cancer Pipeline Assessment 2024: FDA, EMA, PDMA Approvals, Clinical Trials, Drugs, Mechanism of Action, Route of Administration and Companies by DelveInsight here
News-ID: 3511752 • Views: …
More Releases from DelveInsight Business Research
Breast Cancer Biomarker Market Forecast 2032: FDA, EMA and PDMA Approvals, Epide …
(Albany, USA) DelveInsight's "Breast Cancer Biomarker Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Breast Cancer Biomarker, historical and forecasted epidemiology as well as the Breast Cancer Biomarker market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Breast Cancer Biomarker market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and…
Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, C …
(Albany, USA) As per DelveInsight's assessment, globally, Murine Double Minute 2 (MDM2) Inhibitor pipeline constitutes key companies continuously working towards developing Murine Double Minute 2 (MDM2) Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Murine Double Minute 2 (MDM2) Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Murine…
Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline …
(Albany, United States) As per DelveInsight's assessment, globally, Interstitial Lung Disease pipeline constitutes 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Interstitial Lung Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market.
The Interstitial Lung Disease…
Myopia Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechan …
(Albany, USA) As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 10+ pipeline drugs in the Myopia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Myopia Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis…
More Releases for Breast
Breast Ultrasound Market Research Report and Forecast to 2028 - Conventional Bre …
A breast ultrasound is an imaging method chiefly utilized to screen for tumours and other breast abnormalities. The ultrasound use high-frequency sound waves for the production of detailed images of the inside of the breasts.
The global Breast Ultrasound Market is expected to grow at a significant CAGR of 14.6% by 2028.
The updated report on the Breast Ultrasound market gives a precise analysis of the value chain assessment for the review…
Breast Imaging Market by Breast Ultrasound, Breast MRI, Automated Whole-Breast U …
Growth of breast imaging market driven by factors like rising incidence of breast cancer globally, growing government investments and funding for breast cancer treatment and related research, increasing awareness about early detection of breast cancer, rising geriatric population, technological advancements in breast imaging modalities, and launch of advanced breast imaging systems capable of detecting cancer in women with dense breast tissues.
Download Free PDF Brochure on Brest Imaging Market Report Now…
Breast Implants Market Report 2018: Segmentation by Product (Silicone Breast Imp …
Global Breast Implants market research report provides company profile for Allergan, Mentor Worldwide LLC, Hans biomed, Establishment Labs, Polytech Health & Aesthetics, Sientra, Inc., GC Aesthetics, Cereplas and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to…
Automated Breast Ultrasound Systems – The Future of Breast Screening
Breast cancer is the most commonly diagnosed type of cancer and the second leading cause of death among women, as evident from stats revealed by the National Breast Cancer Foundation. Growing awareness of breast cancer has increased number of women undergoing breast screening and in turn would propel demand for automated breast ultrasound systems (ABUS) in hospitals and diagnostic centers. ABUS enables physicians to screen women, especially with denser breasts…
Soaring Instances of Breast Cancer to Propel Breast Imaging Market
"The Report Breast Imaging Market (Mammography, Breast MRI, Breast Ultrasound, Tomosynthesis, Nuclear Imaging and Others [Breast Thermography & Bioelectric Imaging]) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
An intelligence report on the global breast imaging market has been added to the burgeoning portfolio of MarketResearchReports.biz. Titled, “Breast Imaging…
What Is A Combined Breast Augmentation With Breast Lift?
Combined Breast Augmentation And Lift: How Is It Performed?
Surrounding the areola one incisions is made to remove the excess skin and another vertically incisions is made to the base of breasts starting from low part of the areola. Sometimes the scar is referred to as the “Lollipop scar”. Implants are placed through the incisions made and positioned carefully by the surgeon under the pectoral chest muscle, where the implants can…
